- Home
- APM vs AEON Comparison
APM vs AEON Comparison
Compare APM & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- AEON
- Stock Information
- Founded
- APM 2010
- AEON N/A
- Country
- APM United Kingdom
- AEON United States
- Employees
- APM N/A
- AEON N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- AEON Health Care
- Exchange
- APM Nasdaq
- AEON Nasdaq
- Market Cap
- APM 6.9M
- AEON 8.0M
- IPO Year
- APM 2018
- AEON N/A
- Fundamental
- Price
- APM $1.42
- AEON $0.80
- Analyst Decision
- APM
- AEON Strong Buy
- Analyst Count
- APM 0
- AEON 1
- Target Price
- APM N/A
- AEON $360.00
- AVG Volume (30 Days)
- APM 461.1K
- AEON 113.8K
- Earning Date
- APM 08-19-2025
- AEON 08-12-2025
- Dividend Yield
- APM N/A
- AEON N/A
- EPS Growth
- APM N/A
- AEON N/A
- EPS
- APM N/A
- AEON N/A
- Revenue
- APM N/A
- AEON N/A
- Revenue This Year
- APM N/A
- AEON N/A
- Revenue Next Year
- APM N/A
- AEON N/A
- P/E Ratio
- APM N/A
- AEON N/A
- Revenue Growth
- APM N/A
- AEON N/A
- 52 Week Low
- APM $0.46
- AEON $0.38
- 52 Week High
- APM $7.49
- AEON $115.57
- Technical
- Relative Strength Index (RSI)
- APM 51.44
- AEON 56.31
- Support Level
- APM $1.21
- AEON $0.63
- Resistance Level
- APM $1.44
- AEON $0.75
- Average True Range (ATR)
- APM 0.13
- AEON 0.06
- MACD
- APM -0.04
- AEON -0.00
- Stochastic Oscillator
- APM 34.37
- AEON 89.74
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.